title: The anti-addiction drug ibogaine and the heart: a delicate relation.
abstract: The plant indole alkaloid ibogaine has shown promising anti-addictive properties in animal studies. Ibogaine is also anti-addictive in humans as the drug alleviates drug craving and impedes relapse of drug use. Although not licensed as therapeutic drug and despite safety concerns, ibogaine is currently used as an anti-addiction medication in alternative medicine in dozens of clinics worldwide. In recent years, alarming reports of life-threatening complications and sudden death cases, temporally associated with the administration of ibogaine, have been accumulating. These adverse reactions were hypothesised to be associated with ibogaine's propensity to induce cardiac arrhythmias. The aim of this review is to recapitulate the current knowledge about ibogaine's effects on the heart and the cardiovascular system, and to assess the cardiac risks associated with the use of this drug in anti- addiction therapy. The actions of 18-methoxycoronaridine (18-MC), a less toxic ibogaine congener with anti-addictive properties, are also considered.
authors: Department of Neurophysiology and Neuropharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstrasse 17, Vienna 1090, Austria. xaver.koenig@meduniwien.ac.at.
authors: Xaver
authors: X
authors: Koenig
authors: Department of Neurophysiology and Neuropharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstrasse 17, Vienna 1090, Austria. karlheinz.hilber@meduniwien.ac.at.
authors: Karlheinz
authors: K
authors: Hilber
mesh_terms: D000818:Animals; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006213:Hallucinogens / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006329:Heart Conduction System / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007050:Ibogaine / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D008133:Long QT Syndrome / Q000139:chemically induced / Q000503:physiopathology; D012307:Risk Factors; D019966:Substance-Related Disorders / Q000188:drug therapy
chemical_list: D002121:Calcium Channel Blockers; D006213:Hallucinogens; D007050:Ibogaine
references: Circ Res. 1997 Jun;80(6):782-9
references: 9168780
references: J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Nov 7;843(2):131-41
references: 16798116
references: J Cardiovasc Dis Res. 2013 Dec;4(4):229-35
references: 24653586
references: Nature. 2006 Mar 23;440(7083):463-9
references: 16554806
references: Ann N Y Acad Sci. 2000 Sep;914:354-68
references: 11085335
references: Science. 2005 Apr 15;308(5720):345-6
references: 15831735
references: J Forensic Sci. 2012 Mar;57(2):398-412
references: 22268458
references: Drug Metab Dispos. 1998 Aug;26(8):764-8
references: 9698290
references: Arch Int Pharmacodyn Ther. 1985 Jul;276(1):35-43
references: 4051637
references: PLoS One. 2013;8(10):e77262
references: 24204784
references: Fundam Clin Pharmacol. 2002 Apr;16(2):147-56
references: 12031067
references: Fundam Clin Pharmacol. 2010 Oct;24(5):547-59
references: 20584206
references: Ann N Y Acad Sci. 1998 May 30;844:265-73
references: 9668684
references: Clin Toxicol (Phila). 2012 Feb;50(2):157
references: 22304378
references: Clin Toxicol (Phila). 2014 Jul;52(6):642-3
references: 24940646
references: Circulation. 2001 Apr 17;103(15):2004-13
references: 11306531
references: Arch Int Pharmacodyn Ther. 1985 Jul;276(1):60-72
references: 4051640
references: Clin Cardiol. 1999 Sep;22(9):591-4
references: 10486699
references: Circulation. 2010 Mar 2;121(8):1047-60
references: 20142454
references: J Mol Cell Cardiol. 2013 Aug;61:133-41
references: 23702286
references: N Engl J Med. 2009 Jan 15;360(3):308-9
references: 19144953
references: Am J Addict. 2013 May-Jun;22(3):302
references: 23617876
references: J Forensic Leg Med. 2013 Oct;20(7):809-11
references: 24112325
references: J Cardiovasc Pharmacol. 1999 Feb;33(2):181-5
references: 10028924
references: Addict Biol. 2014 Mar;19(2):237-9
references: 22458604
references: J Mol Cell Cardiol. 2007 Mar;42(3):469-77
references: 17289073
references: Nat Rev Drug Discov. 2003 Jun;2(6):439-47
references: 12776219
references: Life Sci. 1996;58(7):PL119-22
references: 8632705
references: J Ethnopharmacol. 2012 Feb 15;139(3):879-82
references: 22200647
references: J Neurophysiol. 2002 Jun;87(6):2867-79
references: 12037190
references: Neth J Med. 2012 Nov;70(9):422-4
references: 23123541
references: Alkaloids Chem Biol. 2001;56:155-71
references: 11705106
references: Hum Exp Toxicol. 2008 Mar;27(3):181-94
references: 18650249
references: Ann N Y Acad Sci. 1998 May 30;844:274-92
references: 9668685
references: Toxicol Appl Pharmacol. 2013 Dec 1;273(2):259-68
references: 23707769
references: J Pharmacol. 1981 Nov-Dec;12(4):441-53
references: 7321573
references: J Clin Pharmacol. 2015 Feb;55(2):189-94
references: 25279818
references: Drug Metab Dispos. 2002 Jun;30(6):663-9
references: 12019193
references: Mol Pharmacol. 2001 Feb;59(2):269-77
references: 11160863
references: Eur J Pharmacol. 2011 Nov 1;669(1-3):71-5
references: 21871879
references: Ann N Y Acad Sci. 2000;909:88-103
references: 10911925
references: Brain Res. 1996 Oct 21;737(1-2):255-62
references: 8930373
references: Circulation. 1996 Feb 1;93(3):407-11
references: 8565156
references: Curr Drug Abuse Rev. 2013 Mar;6(1):3-16
references: 23627782
references: Neuroscience. 1993 Jul;55(2):303-10
references: 8377927
references: Toxicol Sci. 2000 Sep;57(1):95-101
references: 10966515
references: Psychopharmacology (Berl). 1995 Apr;118(4):369-76
references: 7568622
references: Br J Clin Pharmacol. 2012 Nov;74(5):835-41
references: 22369095
references: Ann N Y Acad Sci. 2000 Sep;914:394-401
references: 11085338
references: J Pharmacol Toxicol Methods. 2005 Jul-Aug;52(1):136-45
references: 15950494
references: Cardiovasc Res. 2008 Apr 1;78(1):45-52
references: 18178574
references: Clin Pharmacokinet. 2009;48(11):689-723
references: 19817501
references: Alkaloids Chem Biol. 2001;56:1-38
references: 11705103
references: Pharmacol Rev. 2010 Dec;62(4):760-81
references: 21079043
references: Clin Pharmacokinet. 2002;41(12):913-58
references: 12222994
references: Pharmacology. 2002 Aug;65(4):187-92
references: 12180412
references: Ann N Y Acad Sci. 2000 Sep;914:369-86
references: 11085336
references: J Pharmacol Exp Ther. 2014 Feb;348(2):346-58
references: 24307198
references: J Am Coll Cardiol. 2006 Jan 17;47(2):362-7
references: 16412861
references: Cardiovasc Res. 2003 Apr 1;58(1):32-45
references: 12667944
references: J Pharmacol Exp Ther. 2001 May;297(2):531-9
references: 11303040
references: Brain Res. 1996 May 6;719(1-2):29-35
references: 8782860
references: Ann N Y Acad Sci. 1998 May 30;844:214-26
references: 9668680
references: Arch Int Pharmacodyn Ther. 1957 Mar 1;110(1):92-102
references: 13425751
references: J Clin Invest. 2009 Sep;119(9):2745-57
references: 19726881
references: Cardiovasc Res. 2001 May;50(2):224-31
references: 11334826
references: Br J Anaesth. 2013 Dec;111(6):1029-30
references: 24233315
references: J Forensic Sci. 2013 Nov;58(6):1666-72
references: 23919354
references: Alkaloids Chem Biol. 2001;56:39-53
references: 11705115
references: J Gen Physiol. 2013 Aug;142(2):113-26
references: 23858001
references: Postgrad Med J. 2004 Nov;80(949):654-9
references: 15537850
references: J Cardiovasc Pharmacol. 2010 Oct;56(4):420-30
references: 20930594
references: Brain Res. 1992 Feb 7;571(2):242-7
references: 1377086
references: Eur J Pharmacol. 2006 Jan 20;530(3):243-9
references: 16368090
references: Crit Care Clin. 1997 Oct;13(4):829-48
references: 9330843
references: Nat Prod Lett. 2002 Feb;16(1):71-6
references: 11942686